These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 11356936)
21. Characterization of blood-brain barrier permeability to PYY3-36 in the mouse. Nonaka N; Shioda S; Niehoff ML; Banks WA J Pharmacol Exp Ther; 2003 Sep; 306(3):948-53. PubMed ID: 12750431 [TBL] [Abstract][Full Text] [Related]
22. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Savonenko A; Xu GM; Melnikova T; Morton JL; Gonzales V; Wong MP; Price DL; Tang F; Markowska AL; Borchelt DR Neurobiol Dis; 2005 Apr; 18(3):602-17. PubMed ID: 15755686 [TBL] [Abstract][Full Text] [Related]
23. Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein. Lee KW; Lee SH; Kim H; Song JS; Yang SD; Paik SG; Han PL J Neurosci Res; 2004 May; 76(4):572-80. PubMed ID: 15114629 [TBL] [Abstract][Full Text] [Related]
25. Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. O'Leary TP; Brown RE Behav Brain Res; 2009 Jul; 201(1):120-7. PubMed ID: 19428625 [TBL] [Abstract][Full Text] [Related]
26. Early detection of memory deficits and memory improvement with vaccinia virus complement control protein in an Alzheimer's disease model. Pillay NS; Kellaway LA; Kotwal GJ Behav Brain Res; 2008 Oct; 192(2):173-7. PubMed ID: 18490064 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Carro E; Trejo JL; Gerber A; Loetscher H; Torrado J; Metzger F; Torres-Aleman I Neurobiol Aging; 2006 Sep; 27(9):1250-7. PubMed ID: 16183170 [TBL] [Abstract][Full Text] [Related]
28. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice. LaRue B; Hogg E; Sagare A; Jovanovic S; Maness L; Maurer C; Deane R; Zlokovic BV J Neurosci Methods; 2004 Sep; 138(1-2):233-42. PubMed ID: 15325132 [TBL] [Abstract][Full Text] [Related]
29. Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody. Chauhan NB; Siegel GJ J Neurosci Res; 2002 Jul; 69(1):10-23. PubMed ID: 12111811 [TBL] [Abstract][Full Text] [Related]
30. Early discrimination reversal learning impairment and preserved spatial learning in a longitudinal study of Tg2576 APPsw mice. Zhuo JM; Prescott SL; Murray ME; Zhang HY; Baxter MG; Nicolle MM Neurobiol Aging; 2007 Aug; 28(8):1248-57. PubMed ID: 16828204 [TBL] [Abstract][Full Text] [Related]
31. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133 [TBL] [Abstract][Full Text] [Related]
32. Synaptic transmission is impaired prior to plaque formation in amyloid precursor protein-overexpressing mice without altering behaviorally-correlated sharp wave-ripple complexes. Hermann D; Both M; Ebert U; Gross G; Schoemaker H; Draguhn A; Wicke K; Nimmrich V Neuroscience; 2009 Sep; 162(4):1081-90. PubMed ID: 19477243 [TBL] [Abstract][Full Text] [Related]
33. Beta-amyloid (1-42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex. Jhoo JH; Kim HC; Nabeshima T; Yamada K; Shin EJ; Jhoo WK; Kim W; Kang KS; Jo SA; Woo JI Behav Brain Res; 2004 Dec; 155(2):185-96. PubMed ID: 15364477 [TBL] [Abstract][Full Text] [Related]
34. Transducible P11-CNTF rescues the learning and memory impairments induced by amyloid-beta peptide in mice. Qu HY; Zhang T; Li XL; Zhou JP; Zhao BQ; Li Q; Sun MJ Eur J Pharmacol; 2008 Oct; 594(1-3):93-100. PubMed ID: 18644361 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932 [TBL] [Abstract][Full Text] [Related]
36. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Trinchese F; Liu S; Battaglia F; Walter S; Mathews PM; Arancio O Ann Neurol; 2004 Jun; 55(6):801-14. PubMed ID: 15174014 [TBL] [Abstract][Full Text] [Related]
37. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. Lee HJ; Zhang Y; Zhu C; Duff K; Pardridge WM J Cereb Blood Flow Metab; 2002 Feb; 22(2):223-31. PubMed ID: 11823720 [TBL] [Abstract][Full Text] [Related]
38. Proteomic identification of less oxidized brain proteins in aged senescence-accelerated mice following administration of antisense oligonucleotide directed at the Abeta region of amyloid precursor protein. Poon HF; Farr SA; Banks WA; Pierce WM; Klein JB; Morley JE; Butterfield DA Brain Res Mol Brain Res; 2005 Jul; 138(1):8-16. PubMed ID: 15932783 [TBL] [Abstract][Full Text] [Related]
40. Differential transport of a secretin analog across the blood-brain and blood-cerebrospinal fluid barriers of the mouse. Banks WA; Goulet M; Rusche JR; Niehoff ML; Boismenu R J Pharmacol Exp Ther; 2002 Sep; 302(3):1062-9. PubMed ID: 12183664 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]